Active Not RecruitingNCT05333003
Semaglutide for weight management in people with schizophrenia and obesity
About this title
Read the official source — NCT05333003Medication studyAges 18–70Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- TorontoSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 25, 2022
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 92
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug, Other
- Locations
- Canada
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05333003
- Official title
Show the full official title
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity for Metformin Non-responders: a Single-blind Randomized Control Trial
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
